Reducing IOP: A comparative analysis

Article

An exciting new option in combination with cataract surgery

Phacoemulsification alone has been proven to lower IOP a clinically significant amount over a sustained period of time.1 Cataract surgery also has the added benefit of being considered an extremely safe and effective procedure with limited risks and high quality of life value. With my patients presenting with coexisting pathologies, I am often able to lower their IOPs sufficiently with cataract surgery alone that a combined procedure is not necessary.

When low pressures are needed to prevent visual field loss in patients with moderate to severe glaucoma, trabeculectomy or tube shunts are optimum options. However, they have far more risks associated with them than with cataract surgery alone and studies have also shown that combining these procedures with cataract surgery has a high rate of failure.2

Cataract surgery alone

Transitioning from combined procedures to cataract surgery alone resulted from findings that showed significant reductions in IOP and medication burden were achievable with cataract surgery alone. In a retrospective review of 588 eyes that underwent phacoemulsification and IOL implantation, glaucomatous eyes with preoperative IOPs between 23 to 31 mmHg had a mean 4.8 mmHg reduction in pressure sustained for 10 years.1 While this is good news, additional lowering of IOP could mean a patient is relieved of some medication burden. When planning the treatment of patients with coexistent pathologies, it is expedient to weigh the risk factors and complication rates against the potential overall reduction in pressure and determine what will be maximally beneficial to the patient in the long run.

There is a 90% satisfaction rate in quality of life issues with cataract surgery with a complication rate of less than 5% and very few potential sight threatening risks. In some patients, the greater risk associated with a combined procedure is necessary to take, because a greater pressure reduction is needed, but many patients do not need a drastic reduction in pressure and can benefit from cataract surgery alone.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.